Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice

2018 ◽  
Vol 33 (5) ◽  
pp. 1100-1107 ◽  
Author(s):  
Elena González-Colominas ◽  
María-Carlota Londoño ◽  
Rosa M Morillas ◽  
Xavier Torras ◽  
Sergi Mojal ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Potential Drug

Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice

2020 ◽  
Vol 19 (8) ◽  
pp. 1041-1048
Author(s):  
Vicente Escudero-Vilaplana ◽  
Roberto Collado-Borrell ◽  
Angela Hoyo-Muñoz ◽  
Alvaro Gimenez-Manzorro ◽  
Antonio Calles ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Drug Interactions ◽  
Antineoplastic Agents ◽  
Concomitant Medication ◽  
Potential Drug

Update on New Antifungal Therapy

2007 ◽  
Vol 18 (3) ◽  
pp. 253-260 ◽  
Author(s):  
Paul Juang
Keyword(s):  
Clinical Practice ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Clinical Efficacy ◽  
Antifungal Agents ◽  
Potent Inhibitor ◽  
Fungal Infections ◽  
Potential Drug ◽  
Glucan Synthase ◽  
Ergosterol Synthesis

Increases in rates as well as morbidity and mortality associated with fungal infections have necessitated the need for additional antifungal agents. Recent research has resulted in the introduction of 3 new antifungal agents: micafungin, anidulafungin, and posaconazole. Micafungin and anidulafungin, both potent inhibitor of 1,3-β-D-glucan synthase, are the second and third available agents in the echinocandins class that are available in clinical practice. Posaconazale, a potent inhibitor of ergosterol synthesis, is a new agent in the triazole class that has shown promising clinical efficacy in the treatment and prophylaxis of invasive fungal infections due to Candida as well as molds. This article reviews the clinical efficacy as well as the approved uses and dosages associated with the use of these new antifungal agents. Other considerations, such as precautions, administration techniques, potential drug interactions, and common adverse effects associated with the use of these agents, are also reviewed.

OTC Orlistat Poses Potential Drug Interactions

2006 ◽  
Vol 36 (4) ◽  
pp. 8
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Drug Interactions ◽  
Potential Drug

scholarly journals Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection

2020 ◽  
Author(s):  
Etienne Meriglier ◽  
Claire Rivoisy ◽  
Mojgan Hessamfar ◽  
Noelle Bernard ◽  
Ines Aureau ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cohort Study ◽  
Clinical Practice ◽  
Combination Therapy ◽  
Observational Cohort Study ◽  
Potential Drug ◽  
Clinical Evaluations ◽  
History Of ◽  
Observational Cohort ◽  
Ecg Abnormalities

Abstract Background Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients with moderate/severe COVID-19 infection. Objectives To examine the safety of combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Methods This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines. Results Twenty-one patients received hydroxychloroquine with lopinavir/ritonavir (median age 68 years; 10 males) and 25 received hydroxychloroquine with darunavir/ritonavir (median age 71 years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2–6) days after starting treatment. All ECG abnormalities reversed 1–2 days after interrupting treatment. Four patients died within 14 days. ECG abnormalities were significantly associated with age over 70 years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration. Conclusions Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document